Faron Pharmaceuticals Oy
FPHAF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $12 | $19,542 | $20,730 | $17,369 |
| G&A Expenses | $7 | $8,706 | $7,498 | $9,876 |
| SG&A Expenses | $7 | $9,052 | $7,498 | $9,876 |
| Sales & Mktg Exp. | $246 | $346 | $0 | $0 |
| Other Operating Expenses | $0 | -$26 | -$803 | -$6,137 |
| Operating Expenses | $19 | $28,568 | $27,425 | $21,108 |
| Operating Income | -$19 | -$28,568 | -$27,426 | -$21,108 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$7 | -$2,376 | -$1,304 | -$70 |
| Pre-Tax Income | -$26 | -$30,944 | -$28,730 | -$21,178 |
| Tax Expense | $0 | $0 | $0 | $16 |
| Net Income | -$26 | -$30,944 | -$30,034 | -$21,194 |
| % Margin | – | – | – | – |
| EPS | -0 | -0.341 | -0.381 | -0.291 |
| % Growth | 99.9% | 10.4% | -31% | – |
| EPS Diluted | -0 | -0.341 | -0.381 | -0.291 |
| Weighted Avg Shares Out | 88,518 | 78,641 | 66,764 | 61,317 |
| Weighted Avg Shares Out Dil | 88,518 | 78,641 | 66,764 | 61,317 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $2 | $96 | $165 |
| Interest Expense | $4 | $0 | $1,400 | $235 |
| Depreciation & Amortization | $0 | $197 | $300 | $306 |
| EBITDA | -$18 | -$28,371 | -$27,057 | -$20,802 |
| % Margin | – | – | – | – |